BioAegis Therapeutics Stock
BioAegis Therapeutics develops a portfolio of biomarker-directed treatments across a range of indications.
Sign up today and learn more about BioAegis Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About BioAegis Therapeutics Stock
BioAegis Therapeutics, Inc. develops a portfolio of biomarker-directed treatments for a range of indications. The company was incorporated in 2011 and is based in Morristown, New Jersey.
Funding History
| February 2013 | $3.0M |
|---|---|
| February 2014 | $3.7M |
| April 2015 | $8.0M |
| March 2016 | $1.5M |
| August 2018 | $4.1M |
Management
Corporate Development and Communications
Steven Cordovano
Chief Executive Officer
Susan Levinson
Press
globenewswire - Apr, 7 2024
BioAegis Therapeutics Unveils Upcoming Clinical Study of Gelsolin, an Immune Regulator, as a Treatment for Patients ...finance - Mar, 2 2024
BioAegis Therapeutics Awarded $20 Million BARDA DRIVe Contract to Advance Gelsolin, an Immune Regulator, as a ...biospace - Mar, 22 2022
BioAegis Therapeutics Completes $22 Million Institutional Sale of Equity in a Non-Brokered Transactionglobenewswire - Feb, 17 2022
BioAegis Therapeutics Announces Appointment of Two New Corporate Board MembersEquityZen Recognized As:
